Aurinia Pharmaceuticals Inc
F:IKAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aurinia Pharmaceuticals Inc
F:IKAP
|
CA |
|
Moskovskiy Kreditnyi Bank PAO
MOEX:CBOM
|
RU |
|
Screen Holdings Co Ltd
OTC:DINRF
|
JP |
|
H
|
Housing and Urban Development Corporation Ltd
BSE:540530
|
IN |
|
T
|
thyssenkrupp nucera AG & Co KgaA
OTC:THYKF
|
DE |
|
S
|
Smurfit Kappa Group PLC
F:SK3
|
IE |
|
F
|
Flowserve Corp
XMUN:FWV
|
US |
|
Ziff Davis Inc
NASDAQ:ZD
|
US |
|
Pernod Ricard SA
F:PER0
|
FR |
|
M
|
Mohawk Industries Inc
SWB:MWK
|
US |
|
J
|
Jiangsu Leadmicro Nano Technology Co Ltd
SSE:688147
|
CN |
|
Compania de Minas Buenaventura SAA
F:MBU
|
PE |
|
T
|
Tourism Holdings Ltd
ASX:THL
|
NZ |
|
CleanBnB SpA
MIL:CBB
|
IT |
|
Travis Perkins PLC
F:LFPB
|
UK |
|
C
|
Cuscal Ltd
ASX:CCL
|
AU |
|
G
|
Galan Lithium Ltd
F:9CH
|
AU |
|
Namura Shipbuilding Co Ltd
F:8AF
|
JP |
|
Ta Chen Stainless Pipe Co Ltd
TWSE:2027
|
TW |
|
Swatch Group AG
F:UHR
|
CH |
|
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
|
IN |
Wall St Price Targets
IKAP Price Targets Summary
Aurinia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for IKAP is 10.13 EUR with a low forecast of 8.85 EUR and a high forecast of 12.88 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IKAP's stock price target?
Price Target
10.13
EUR
According to Wall Street analysts, the average 1-year price target for IKAP is 10.13 EUR with a low forecast of 8.85 EUR and a high forecast of 12.88 EUR.
What is the Revenue forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
16%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 16%.
What is the Gross Profit forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
22%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 33%. The projected CAGR for the next 3 years is 22%.
What is the Operating Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
24%
The compound annual growth rate for Operating Income over the next 8 years is 24%.
What is the Pre-Tax Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
33%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 33%.
What is the Net Income forecast for Aurinia Pharmaceuticals Inc?
Projected CAGR
6%
The compound annual growth rate for Net Income over the next 8 years is 6%.
